Ziopharm Oncology (ZIOP) gets approval from the RAC to run a Phase 1 study of Ad-RTS-IL-12 in brain cancer.
The company expects to launch the study in H1 of next year.
Ad-RTS-IL-12 is in Phase 2 testing for melanoma and breast cancer. (PR)
Reminder: Ad-RTS-IL-12 is developed with a controlled expression platform from Intrexon (XON).
ZIOP +10.3% premarket